Pharmaceutical Corruption Media ArticlesExcerpts of Key Pharmaceutical Corruption Media Articles in Major Media
Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.
The Food and Drug Administration knew that some doctors were wrongly prescribing powerful opioid painkillers. The drugs include mouth sprays and lozenges meant to provide immediate relief for breakthrough cancer pain ... in patients who have been taking opioids for long periods of time. The formulations, referred to as transmucosal immediate-release fentanyl products, or TIRF products, can kill patients who take them without having first developed tolerance. But they were prescribed to patients who had no tolerance, and for migraines or dental pain, the team at the Johns Hopkins Bloomberg School of Public Health said. The U.S. is suffering through an epidemic of opioid abuse. Opioids, including prescription opioids and heroin, killed 42,000 people in 2016. At the same time, the CDC reported last year, the number of prescriptions for the painkillers tripled from 1999 to 2015. The FDA set up a special plan to control [TIRF products], called a risk evaluation and mitigation strategy. The FDA asked one of its expert panels ... to help review how the strategy for the TIRF opioids has been working. It has not worked as designed, the Johns Hopkins team said in testimony given to the panel. The strategy has "generated red flags for years," the team said in written testimony. “FDA had evidence as early as April 2016 that TIRFs were being prescribed for many patients who were not opioid tolerant,” they wrote in their testimony. “Of more than 25,000 patients receiving TIRFs, as many as 51 percent were not opioid tolerant.”
Note: A recent CNN report titled, "The more opioids doctors prescribe, the more money they make" shows how doctors have profited from over-prescribing these dangerous drugs. For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in Big Pharma.
The US government missed the opportunity to curb sales of the drug that kickstarted the opioid epidemic when it secured the only criminal conviction against the maker of OxyContin a decade ago. Purdue Pharma hired Rudolph Giuliani, the former New York mayor and now Donald Trump’s lawyer, to head off a federal investigation in the mid-2000s into the company’s marketing of the powerful prescription painkiller at the centre of an epidemic estimated to have claimed at least 300,000 lives. While Giuliani was not able to prevent the criminal conviction over Purdue’s fraudulent claims for OxyContin’s safety and effectiveness, he was able to reach a deal to avoid a bar on Purdue doing business with the federal government which would have killed a large part of the multibillion-dollar market for the drug. The former New York mayor also secured an agreement that greatly restricted further prosecution of the pharmaceutical company and kept its senior executives out of prison. The US attorney who led the investigation, John Brownlee, has ... expressed surprise that Purdue did not face stronger action. Purdue is now facing ... civil lawsuits [in] New York, Texas and five other states. But Brownlee was the first, and so far only, prosecutor to secure a criminal conviction against the drug maker. Brownlee’s office discovered training videos in which reps acted out selling the drug using the false claims. “This was ... pushed from the highest levels of the company,” said Brownlee.
Pharmaceutical companies that spend billions of dollars to develop new drugs do not want competitors to profit from inexpensive generic copies of blockbuster medicines. To avoid rivals, they ... sometimes prevent generic drug companies from obtaining samples. Dr. Scott Gottlieb, the commissioner of the Food and Drug Administration, calls this “gaming the system,” and has vowed to stop it. On Thursday, the F.D.A. took a new tack and began posting a list of makers of brand-name drugs that have been the target of complaints, to persuade them to “end the shenanigans,” in the commissioner’s words. Congressional efforts to force the companies to hand over samples of their drugs to generic competitors have not been successful. Generic drug developers usually need between 1,500 to 5,000 units of the brand drug to develop their product and test it. Both the F.D.A. and the Federal Trade Commission say securing the samples can be difficult. The F.D.A.’s new list includes drug companies the agency said may be pursuing gaming tactics to delay generic competition. Along with the name of each business, the agency noted how many inquiries it received from generic drug companies seeking supplies. Celgene, [which makes drugs to treat cancer and immune-inflammatory diseases], tops the list. Other companies ... included GlaxoSmithKline, Pfizer, Valeant Pharmaceuticals International, BioMarin Pharmaceutical, Gilead Sciences and Novartis Pharmaceuticals.
Note: For more along these lines, see concise summaries of deeply revealing Big Pharma corruption news articles from reliable major media sources.
One very expensive prescription drug threatened to financially cripple an entire city. Rather than using a health insurance company, Rockford, [Illinois] has, for years, paid its own health care costs for its 1,000 employees and their dependents. When Rockford got hit with the drug bill it was so enormous the mayor at the time set out to understand why. In 2015, two small children of Rockford employees were treated with Acthar, a drug that's been on the market since 1952. In 2001, Acthar sold for about $40 a vial. Today: more than $40,000. [Rockford Mayor Larry Morrissey] wanted to know how that could've happened. His investigation got nowhere until last year, when the Federal Trade Commission charged the drug manufacturer, Mallinckrodt, with violating antitrust laws. [The company] bought another drug that was Acthar's main competitor ... and put it on the shelf. Many of the doctors who prescribed a lot of Acthar also were getting money from the company that makes Acthar ... adding up to huge sums. Cities like Rockford [hire pharmacy benefit managers or PBMs] to negotiate down the price of drugs. The company negotiating prices for Rockford is Express Scripts. Express Scripts is many companies, not just the PBM. It also owns a pharmacy that sells expensive drugs, [as well as] a company that ships and packs expensive drugs. The city of Rockford was able to find out one more piece of the puzzle: that Express Scripts ... had a contract to be the exclusive distributor of Acthar.
Note: For more along these lines, see concise summaries of deeply revealing Big Pharma corruption news articles from reliable major media sources.
It looks like an ordinary commercial warehouse, only much bigger. When the lights come on, hundreds of thousands of shrink-wrapped boxes of medicines emerge from the gloom, stacked on shelves nearly five stories high. This [warehouse] and several others across the country are part of the $7 billion Strategic National Stockpile, a government repository of drugs and supplies ready for deployment in a bioterrorism or nuclear attack, or ... other major public health emergency. For nearly two decades, the repository has been almost exclusively managed by the Centers for Disease Control and Prevention. That will change under a Trump administration plan to shift oversight of the $575 million program. Public health officials and members of Congress ... worry the move will disrupt a complex process that relies on long-standing relationships. Experts also question whether the administration’s plan will politicize decision-making about products bought for the stockpile. The office of the assistant secretary for preparedness and response (ASPR) oversees the process by which the government awards contracts to private biotechnology companies that develop and manufacture medicines. The CDC then is responsible for buying and replenishing the materials. Come October, however, the ASPR will be in charge of choosing the products and then purchasing them for the stockpile. Critics say it will allow biotech companies to lobby for more of their specialized, and often more expensive, drugs to be included.
Note: With a $7 billion price tag, big Pharma is making money hands over fist on this repository which is almost never used. Most of these drugs have a shelf life of well under 10 years, so major parts of this huge inventory go to waste every year and have to be disposed of. For more along these lines, see concise summaries of deeply revealing news articles on government corruption and Big Pharma profiteering from reliable major media sources.
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run. "Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution." "The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow." Richter cited Gilead Sciences' treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company's U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. "GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients," the analyst wrote. "In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients, thus the incident pool also declines. Where an incident pool remains stable (eg, in cancer) the potential for a cure poses less risk to the sustainability of a franchise."
Note: Many cancer treatments have been suppressed, sometimes in brutal ways, because the medical profession would lose the huge profits of traditional cancer treatments. Watch this video for undeniable evidence showing that this is the case. Read an excellent article on how the profiteering drug industry is crippling our children, possibly even intentionally. For more along these lines, see concise summaries of deeply revealing health news articles from reliable major media sources.
Antibiotic resistance contributes to the death of 700,000 people around the world each year. Experts have predicted it will eclipse the number of people affected by cancer by 2050. One of the biggest causes is the overuse of antibiotics. On Monday, a group led by researchers from the Center for Disease Dynamics, Economics and Policies released a new study looking at the global consumption of antibiotics. They found the use of antibiotics worldwide has increased 65 percent from 2000 to 2015. What happens is, antibiotics kill bacteria that make us sick. But the bacteria over time evolve and develop an ability to survive the onslaught of the antibiotics. They, in essence, get smart. So, over time, bacteria survive that have resistance built in. The biggest contributor to this problem is in low- to mid-income countries. Back in 2000, the usage of antibiotics in the lower- to mid-income countries vs. high-income countries was about equal. In 2015, the usage in those low- to mid-income countries doubled. The projections are, by 2030, our use of antibiotics, if nothing changes, will be triple what it is today. And what that means is, there are going to be many more antibiotics which become really just basically useless, more so-called superbugs out there. And we are facing the prospect of a post-antibiotic world. We could get back to a world ... where something as simple as a cut or a blister could kill you, which is what the world was like before we had antibiotics.
Note: For more along these lines, see concise summaries of deeply revealing news articles on health from reliable major media sources.
As tens of thousands of Americans die from prescription opioid overdoses each year, an exclusive analysis by CNN and researchers at Harvard University found that opioid manufacturers are paying physicians huge sums of money - and the more opioids a doctor prescribes, the more money he or she makes. The CNN/Harvard analysis looked at 2014 and 2015, during which time more than 811,000 doctors wrote prescriptions to Medicare patients. Of those, nearly half wrote at least one prescription for opioids. Fifty-four percent of those doctors - more than 200,000 physicians - received a payment from pharmaceutical companies that make opioids. Among doctors in the top 25th percentile of opioid prescribers by volume, 72% received payments. Among those in the top fifth percentile, 84% received payments. Among the very biggest prescribers ... 95% received payments. On average, doctors whose opioid prescription volume ranked among the top 5% nationally received twice as much money from the opioid manufacturers, compared with doctors whose prescription volume was in the median. Pharmaceutical company payments to doctors are not unique to opioids. Drug companies pay doctors billions of dollars for various services. In 2015, 48% of physicians received some pharmaceutical payment. The CNN and Harvard findings are in line with other studies suggesting that money from drug companies does influence a doctor's prescribing habits.
Note: From 1999 to 2015, over 183,000 people died from prescription opioid overdoses in the US. A CBS article titled, "Ex-DEA agent: Opioid crisis fueled by drug industry and Congress" describes major regulatory failures that contributed to this crisis. For more along these lines, see concise summaries of deeply revealing Big Pharma corruption news articles from reliable major media sources.
When nurse Meleney Gallagher was told to line up with her colleagues on the renal ward at Sunderland Royal Hospital, for her swine flu vaccination, she had no idea the injection she was about to have had not gone through the usual testing process. It had been rushed into circulation after the swine flu virus had swept across the globe in 2009. Gallagher was one of thousands of NHS staff vaccinated with Pandemrix, a vaccine made by pharmaceutical giant GlaxoSmithKline (GSK). Eight years later, her career in the NHS is a memory and she's living with incurable, debilitating narcolepsy and suffers from cataplexy, a sudden, uncontrollable loss of muscle tone that can cause her to collapse without warning. Because of her condition, she can no longer work or drive. People with narcolepsy experience chronic fatigue and difficulty sleeping at night. They can have night terrors, hallucinations, and a range of mental health problems. Gallagher is not alone. More than a dozen frontline NHS staff are among around 1,000 adults and children across Europe who are believed to have developed narcolepsy after being given Pandemrix. Gallagher and four other NHS professionals – two nurses, a community midwife, and a junior doctor – have told how they felt pressured into receiving the vaccine, were given misleading information, and ultimately lost their careers. They are all suing GlaxoSmithKline seeking compensation for what they believe was a faulty drug that has left them with lifelong consequences.
Note: Yet the media and big Pharma continually tout the safety of their vaccines. For more along these lines, see concise summaries of deeply revealing news articles on vaccines from reliable major media sources.
Over the past decade, nearly 21 million prescription painkillers have been shipped to a tiny town in West Virginia, a state where more people have overdosed on opioids and died than in any other in the nation. 20.8 million hydrocodone and oxycodone pills have been delivered to Williamson, W.Va., a town with ... fewer than 3,200 residents. [House Energy and Commerce] Committee leaders sent letters to two regional drug distributors, asking why the companies oversupplied this town, among others, with painkillers. “These numbers are outrageous,” Reps. Greg Walden (R-Ore.) and Frank Pallone Jr. (D-N.J.) said in a statement. Attorney General Jeff Sessions on Tuesday announced a nationwide crackdown on pharmacies and prescribers that are oversupplying opioids amid a deadly epidemic sweeping the United States. In the letters, dated Jan. 26, the congressional committee noted that between 2006 and 2016, drug distributors shipped large quantities of hydrocodone and oxycodone to two pharmacies in Williamson. During that time, Tug Valley Pharmacy received more than 10.2 million pills and Hurley Drug Company received more than 10.5 million pills. The pharmacies are 0.2 miles apart. The committee said in a letter to distributor Miami-Luken that from 2008 to 2015, the company had supplied more than half of all the prescription pain pills shipped to Tug Valley Pharmacy. And distributor H.D. Smith, the committee said, provided the pharmacies with nearly 5 million pills between 2007 and 2008.
Note: A CBS article titled, "Ex-DEA agent: Opioid crisis fueled by drug industry and Congress" describes major regulatory failures that contributed to this addiction crisis. For more along these lines, see concise summaries of deeply revealing Big Pharma corruption news articles from reliable major media sources.
Hospital executives have expressed frustration when essential drugs like heart medicines have become scarce, or when prices have skyrocketed. Now, some of the country’s largest hospital systems are taking an aggressive step to combat the problem: They plan to go into the drug business themselves, in a move that appears to be the first on this scale. “This is a shot across the bow of the bad guys,” said Dr. Marc Harrison, the chief executive of Intermountain Healthcare, the ... hospital group that is spearheading the effort. Several major hospital systems, including ... the nation’s largest nonprofit hospital group, plan to form a new nonprofit company, that will provide a number of generic drugs to the hospitals. The Department of Veterans Affairs is also expressing interest in participating. The idea is to directly challenge the host of industry players who have capitalized on certain markets, buying up monopolies of old, off-patent drugs and then sharply raising prices, stoking public outrage and prompting a series of Congressional hearings and federal investigations. The most notorious example is of Martin Shkreli, the former hedge fund manager who raised the price of a decades-old drug, Daraprim, to $750 a tablet in 2015, from $13.50. Hospitals have also struggled to deal with shortages of hundreds of vital drugs over the past decade, ranging from injectable morphine to sodium bicarbonate (the medical form of baking soda), shortfalls that are exacerbated when only one or two manufacturers make the product.
Note: Americans pay the highest prices for medications in the world, and many US government policies appear designed to keep drug prices high. For more along these lines, see concise summaries of deeply revealing Big Pharma profiteering news articles from reliable major media sources.
In the 1970s, a truth was accidentally discovered about depression. American psychiatrists had produced a book ... called the Diagnostic and Statistical Manual [that] laid out nine symptoms that a patient has to show to be diagnosed with depression. If [doctors] followed this guide, they had to diagnose every grieving person who came to them as depressed. So, the doctors wanted to know, are we supposed to start drugging all the bereaved people in America? The authors ... decided that there would be a special clause added to the list of symptoms. If you have lost somebody you love in the past year ... all these symptoms are natural, and not a disorder. It was called “the grief exception”. Then ... doctors on the frontline started to come back with another question. If you agree that the symptoms of depression are a logical and understandable response to one set of life circumstances – losing a loved one – might they not be an understandable response to other situations? What about if you lose your job? What if you are stuck in a job that you hate? What about if you are alone and friendless? The grief exception seemed to have blasted a hole in the claim that the causes of depression are sealed away in your skull. It suggested that there are causes out here, in the world, and they needed to be investigated and solved there. Depression ... is a signal that your natural psychological needs are not being met. It is a form of grief – for yourself, and for the culture you live in going so wrong.
Note: The article at the link above is an edited extract from Lost Connections: Uncovering the Real Causes of Depression – and the Unexpected Solutions by Johann Hari. A 2012 Huffington Post article titled, "Drug Companies Drive the Psychiatric Drugging of Children" describes how fake science and bribes have been used by corrupt pharmaceutical companies to rake in the profits.
Prices for a cancer drug called lomustine have skyrocketed nearly 1,400 percent since 2013, putting a potentially life-saving treatment out of reach for patients suffering from brain tumors and Hodgkin's lymphoma. Though the 40-year-old medication is no longer protected by patents, no generic version is available. According to the Wall Street Journal, lomustine was sold by Bristol-Myers Squib for years under the brand name CeeNU at a price of about $50 a capsule for the highest dose. The drugmaker sold lomustine in 2013 to a little-known Miami startup called NextSource, which proceeded to hike lomustine's price nine times since. It now charges about $768 per pill for the medication. According to an analysis done for the Journal ... NextSource this year raised prices for the drug, which it rebranded as Gleostine, by 12 percent in November following a 20 percent increase in August. Soaring prices for cancer drugs are a concern for both patients and doctors because financial pressures can lead to delays in seeking treatment that can easily surpass six figures per year. A study published earlier this year in the Journal of Clinical Oncology found prices for 24 patented injectible Medicare Part B drugs rose an average of 18 percent annually over the past eight years on an inflation-adjusted basis. Prices continued to rise even when generic versions of the drug became available.
Note: For more along these lines, see concise summaries of deeply revealing Big Pharma profiteering news articles from reliable major media sources.
Television advertisements for prescription drugs ... have been running for 20 years. [Yet] it is not your imagination if you think you are seeing more of them these days. Lots more. 771,368 such ads were shown in 2016 ... an increase of almost 65 percent over 2012. “TV ad spending by pharmaceutical companies has more than doubled in the past four years, making it the second-fastest-growing category on television during that time,” Jon Swallen, Kantar’s chief research officer, said. The ads ... have turned to more serious ailments in the last few years. And when the ads come on, [the] audience is also listening intently to all that can befall them if they take a certain drug. An unexpected side effect of ad agency compliance with the drug administration’s regulation, it turns out, is enhanced credibility. “It’s counterintuitive, but everything in our research suggests that hearing about the risks increases consumers’ belief in the advertising,” said Jeff Rothstein, the chief executive officer of Cult Health, an ad agency that specializes in health care.
Note: 25 years ago drug advertising was illegal, as it was believed drugs should sell themselves on their own merits. Now Big Pharma is raking in profits hand over fist by inundating us with fear-based advertising. For more along these lines, see concise summaries of deeply revealing Big Pharma profiteering news articles from reliable major media sources.
After months of deliberation and investigation, the WHO has concluded that cannabidiol (CBD) is a useful treatment for epilepsy and palliative care, and does not carry any addiction risks. The organization is set to run a fuller review of cannabis next year. The report ... also recommended imposing the strong restrictions available on fentanyl, a synthetic opioid which has killed thousands of people in America’s drug addiction epidemic. “There is increased interest from Member States in the use of cannabis for medical indications including for palliative care,” the report said. “Responding to that interest and increase in use, WHO has in recent years gathered more robust scientific evidence on therapeutic use and side effects of cannabis and cannabis components.” In conclusion, the authors wrote: “Recent evidence from animal and human studies shows that its use could have some therapeutic value for seizures due to epilepsy and related conditions.” They added that ‘current information does not justify scheduling of cannabidiol’, and declared that taking medical marijuana will not lead to addiction to THC, the psychoactive property of cannabis that induces a ‘high’.
Note: More people are arrested in the US for marijuana use than for all violent crimes combined and the US federal government continues to regard non-psychoactive CBD as a dangerous drug. The UK government recently announced it will regulate CBD as medicine. For more along these lines, see concise summaries of deeply revealing health news articles from reliable major media sources.
For decades, Don Anderson of Seattle has been taking the same drug to help control the temporary bouts of immobility and muscle weakness caused by a rare and frightening genetic illness called periodic paralysis. The drug Anderson has been taking all these years was originally approved in 1958 and used primarily to treat the eye disease glaucoma under the brand name Daranide. The price has been on a roller coaster in recent years — zooming from a list price of $50 for a bottle of 100 pills in the early 2000s up to $13,650 in 2015, then plummeting back down to free, before skyrocketing back up to $15,001 after a new company, Strongbridge Biopharma, acquired the drug and relaunched it this spring. The zigzagging trajectory of the price of Daranide, now known as Keveyis, shows just how much freedom drug companies have in pricing therapies — and what a big business opportunity selling extremely-rare-disease drugs has become. In 2016, after The Washington Post asked questions about the high price of the drug, Sun Pharmaceutical said it would give the drug away free. Late last year, Sun agreed to sell Keveyis to a biotech company, Strongbridge Biopharma. In April, Strongbridge relaunched the drug. In August, it jacked the list price ... to $15,001 for a bottle of 100 pills. In a PowerPoint presentation for investors, Strongbridge Biopharma estimated that the annual price of treatment for the drug, Keveyis, would range from $109,500 to $219,000.
Note: For more along these lines, see concise summaries of deeply revealing Big Pharma corruption news articles from reliable major media sources.
The World Health Organization said on Monday it hoped to conduct a full review by the end of the year of a dengue vaccine that was suspended last week in the Philippines. On Friday, the department of health halted its dengue immunization program after the manufacturer, French drug company Sanofi Pasteur, announced the vaccine, [commonly known as Dengvaxia], must be strictly limited due to evidence it can worsen dengue in people not previously exposed to the infection. The government of Brazil, where dengue is common, confirmed it already had recommended restricted use of the vaccine. Amid mounting public concern, Sanofi explained its "new findings" at a news conference in Manila on Monday but did not say why action was not taken after a WHO report in mid-2016 that identified the risk the company was now flagging. Nearly 734,000 children ... in the Philippines have received one dose of the vaccine as part of a programme that cost 3.5 billion pesos (more than $80 million Cdn). The Philippines Department of Justice on Monday ordered the National Bureau of Investigation to look into "the alleged danger to public health ... and if evidence so warrants, to file appropriate charges." There was no indication that Philippines health officials knew of any risks. However, the WHO said in a July 2016 research paper that "vaccination may be ineffective or may theoretically even increase the future risk" of severe dengue illness in people who hadn't been exposed to it prior to their first vaccination.
Note: Read more about this and about the way vaccines dangers are being covered up on this webpage. For more along these lines, see concise summaries of deeply revealing vaccine controversy news articles from reliable major media sources.
The Philippines ordered an investigation on Monday into the immunization of more than 730,000 children with a vaccine for dengue that has been suspended following an announcement by French drug company Sanofi that it could worsen the disease in some cases. The World Health Organization said it hoped to conduct a full review by year-end of data on the vaccine, commercially known as Dengvaxia. In the meantime, the WHO recommended that it only be used in people who had a prior infection with dengue. The government of Brazil, where dengue is a significant health challenge, confirmed it already had recommended restricted use of the vaccine but had not suspended it entirely. Amid mounting public concern, Sanofi explained its "new findings" at a news conference in Manila but did not say why action was not taken after a WHO report in mid-2016 that identified the risk it was now flagging. A non-governmental organization (NGO) said it had received information that three children who were vaccinated with Dengvaxia in the Philippines had died and a senator said he was aware of two cases. Last week, the Philippines Department of Health halted the use of Dengvaxia after Sanofi said it must be strictly limited due to evidence it can worsen the disease in people not previously exposed to the infection. Nearly 734,000 children aged 9 and over in the Philippines have received one dose of the vaccine as part of a program that cost 3.5 billion pesos ($69.54 million).
Note: This US government webpage states, "Since 1988, over 18,897 petitions have been filed with the VICP [Vaccine Injury Compensation Program]. Over that 29-year time period, 16,857 petitions have been adjudicated, with 5,782 of those determined to be compensable. Total compensation paid over the life of the program is approximately $3.7 billion." Why aren't these large numbers being reported in the media? For more along these lines, see concise summaries of deeply revealing vaccine controversy news articles from reliable major media sources.
Regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken. The digital pill combines two existing products: the former blockbuster psychiatric medication Abilify - long used to treat schizophrenia and bipolar disorder - with a sensor tracking system first approved in 2012. Experts say the technology could be a useful tool, but it will also change how doctors relate to their patients as they’re able to see whether they are following instructions. The pill has not yet been shown to actually improve patients’ medication compliance, a feature insurers are likely to insist on before paying for the pill. Additionally, patients must be willing to allow their doctors and caregivers to access the digital information. The technology carries risks for patient privacy, too, if there are breaches of medical data or unauthorized use as a surveillance tool, said James Giordano, a professor of neurology at Georgetown University Medical Center. “Could this type of device be used for real-time surveillance? The answer is of course it could,” said Giordano. The new pill, Abilify MyCite, is embedded with a digital sensor that is activated by stomach fluids, sending a signal to a patch worn by the patient and notifying a digital smartphone app that the medication has been taken.
Note: In 2010, it was quietly reported that Novartis AG would be seeking regulatory approval for such "chip-in-a-pill technology". For more along these lines, see concise summaries of deeply revealing news articles on microchip implants and the disappearance of privacy.
The nation’s leading heart experts on Monday issued new guidelines for high blood pressure that mean tens of millions more Americans will meet the criteria for the condition. Under the guidelines ... the number of men under age 45 with a diagnosis of high blood pressure will triple, and the prevalence among women under age 45 will double. The number of adults with high blood pressure, or hypertension, will rise to 103 million from 72 million under the previous standard. The number of people who are new candidates for drug treatment will rise ... by an estimated 4.2 million people. To reach the goals others may have to take more drugs or increase the dosages. The change is due largely to convincing data from a federal study published in 2015. That study, called Sprint, explored whether markedly lower blood pressure in older people - lower than researchers had ever tried to establish - might be both achievable and beneficial. In participants who were assigned to get their systolic pressures below 120, the incidence of heart attacks, heart failure and strokes fell by a third, and the risk of death fell by nearly a quarter. But more intensive drug treatment in so many more patients may increase rates of kidney disease. In the Sprint trial, the incidence of acute kidney injury was twice as high in the group receiving drugs to reduce their systolic pressure to 120. Lifestyle changes like diet and exercise can help many patients lower blood pressure. But many of the newly diagnosed are likely to wind up on drugs.
Note: The effect of this huge change is that billions more dollars will now flow into Big Pharma as millions of consumers are led to believe their blood pressure is dangerously high. Are drugs the best answer? For more along these lines, see concise summaries of deeply revealing news articles on pharmaceutical industry corruption and health.
Important Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.